By: cson fzd
[Recommend this Fotopage] |
[Share this Fotopage]
View complete fotopage
View complete fotopage
|Thursday, 10-May-2012 11:27
||Email | Share | Bookmark
The year 2009 new drugs and biological products
The report on the 2009 51 listingof new drugs and vaccines made thorough review, introduces some new mechanisms of action and development trend ,and in 2010 will be listed ondrug and vaccine was made forecast .
This report annually published in the Thomson Reuter journal drug news and prospects ,and the absorption of Prous Science Integrity views and information .Prous Science Integrity complete drug development path Prous Science Integrity has integrated more than 315000 chemicaland biological activity of molecular biological activity data ,there are tens of thousands of intermediates and 135000 patentdrug data .
These daily updated data ,provides a complete ,comprehensive information ,help to promote innovation ,support in the early stages of development to make quick ,strategic decision .By pharmaceutical scientists and experts in the design ,assembly ,refining and support system to provide unique knowledge to boost your R & D activities.
For more information, please refer to :go.thomsonreuters.com / integrity drugs and biological products in 2009 2009a total of 51have a role in the treatment ofchemical molecular entity biological products and market.
In this twenty-second edition of the annual drug and biological preparation Products show the past year of new chemical and biological products of history and prospects of research on these drugs .
The information for the current drug development to provide reference ,especially introduced and existing drugs with different action mechanisms in the new generation of compounds and the use of innovative drug R & D method after the emerge of new therapeutic molecules.
According to our records ,Embarrassment of Chinese core,in 2009 a total of 51listed thenew chemical and biological products ,is the past 10 years the largest number of first time . 2009 12 othernew products approved, but in the end was not listed .
Continue the trend in recent years ,a total of 24 "improved " ;new drug ( the new dosage forms of drugs already on the market ,new indications and new complexes ) approved, will account for the annual review of drug 32%.
Over the past year, immune modulators and immune system related to drug research and development is one of the most active fields ( Table 1) ,a total of 17 newproducts ,most of which are aimed at the 2009 H1N1 fluvaccine .
The United States once again become the most active new drugs listed on the single market ,in 2009 a total of 24 new products,50% of the total.EU with 18 followed by( Figure 1 ).The information in the report originates and business exchanges and Thomson Reuters Prous Science Integrity database product according to the treatment field and the mechanism of action of classification .
According to the treatment area classification of drugs and biologics Abstract This article presents an annual annual listing of the new drugs and biological products . 2009, 51new medicines and vaccinesto appear on the market first .
" ;improved " ;drug ( already listed drug new formulations, new indications and new complexes ) accounted for all the new product of more than 30%. In addition to providing an annual listing of drug and biological products overview ,this article further interpretation of a class of drugs ,so that readers can get a better understanding of their mechanisms of action ;also on these the drug development process is analyzed ;and more comprehensive provides the drug repositioning and prolong the drug life cycle strategies.
We also selective for the foreseeable future will start the listed drugs and biological products are briefly introduced in the paper. Narcotic drugs in 2009 June Ortho-McNeil-Janssentapentadol hydrochloride ( novel analgesics NucyntaTM ) appear on the market, and this is Gruenenthal cooperation in research and development of new oral analgesics ,first in the United States listed .
Is a kind of double power Effect of complexes ,both opoid receptor antagonist ,and norepinephrine reuptake inhibitor ,approved by the FDA for over 18 years in adult patients with severe acute pain treatment .
According to various acute pain patients was phase three clinical trials, compared to the placebo group ,medication group subjects pain have been greatly remission. The United States drug regulatory agencies listed tapentadol is II kind of controlled drugs.
In 2009 Augustapproved by the FDA King Embeda ( morphine sulfate / cyproterone methyl hydroxy two morphine ondansetron hydrochloride sustained release oral capsule preparation ) ,the medicine in the following month listed .
Embeda is a long-term II opioid analgesics for moderate to severe pain ,provide long-lasting analgesic therapy . Embeda capsule contains a prolonged release of morphine pellets ,each pellet containing a cyclopropane carbonyl hydroxyl two morphine ondansetron core .
The overall taking this special design preparation ,morphine will relieve the pain, cyproterone methyl hydroxy two morphine ondansetron does not produce can be observed clinical effect. However ,if the capsule is crushed or chewed after ingestion ,cyproterone methyl hydroxy two strong hydromorphone and morphine together will be released and absorbed ,reverse opioid individual and the analgesic effect ,thereby preventing drug Addiction .
FDA based on 12 clinical trial datato the drug approval, including reflect the efficacy and safety of three phase of experimental data .NeurogesX Qutenza is a vanilloid VR1 receptor antagonist capsaicin transdermal preparation ,the drug in the United States and the European Union last year to obtain different indications for approval.
The product is approved in May Europe ,used in non diabetic patients with peripheral neuropathic pain treatment ,can be used alone or in combination with other analgesic drugs in the United States .
The drug is approved for use in neuropathic joint zoster neuralgia pain management .The effect of Qutenza on the occurrence of pain skin area to determine the neural .This transdermal formulations can provide up to 12 weeks of pain relief efficacy.
The medicine will be held on 2010 in Europe ,sold by Astellas company in the United States .The medicine has the rare disease therapeutic drug identity. Although in several countries have been based on capsaicin pain relief products ,ADIDAS Porsche Design P5000,but this is the first long-term transdermal formulations .
The middle of November ,Eisai company in the United States announced that fospropofol two sodium hydrogen phosphate ( Lusedra ) success ,this is a kind of intravenous analgesia hypnotics ,for diagnostic or therapeutic procedures in adult patients with anesthesia monitoring .
The product is a unique water soluble preparation ,through static After intravenous injection ,in vivo by alkaline phosphatase activity into active components. In the approval document ,On the metaphysical puzzle,FDA requires that the drug must be approved by the professional training of personnel ,for adult patients with general anesthesia ,the anesthesia and during the recovery patients must be monitored .
Lusedra belongs to the whole class IV tube pharmaceutical .Novalar pharmaceutical company drug is listed last year OraVerseTM ,this is a a-adrenoceptor antagonist and a vasodilator phentolamine methyl sulfonyl new agents ,in the United States for dental anesthesia after recovery.
The United States each year about 3 hundred million ofdental local anesthesia case .Although widely used, but dental anesthesia is easy to cause the useless in anesthesia and loss of function .
OraVerse is the first the use of containing a vasoconstrictor dental local anesthetic to soft tissue anesthesia and concomitant loss of function has the reverse effect of the drug ,can accelerate the recovery of normal sensory and functional .
Psychological treatment Bupropion has proved to be an effective antidepressant drugs ,can quickly relieve symptoms of depression ,and a low recurrence rate. The drug is dopamine reuptake inhibitors ,1989 has beenlisted .
Last year, exactly 20 years after the launch of Aplenzin ,Biovail and Sanofi-Aventis ( bupropion hydrogen Bromate) ,this is a day only once-daily bupropion salt . Aplenzin for adults over 18 years of severe depressive disorder treatment .
Lilly Symbyax olanzapine and fluoxetine hydrogen chloride fixed dose compounds ,last year in the United States approved a new indication for the treatment of drug resistance have listed :the depression ( on two separate adequate antidepressant treatment invalid serious depressive disorder ) treatment .
Symbyax2004 yearlisted for depression and bipolar disorder treatment. This product will be atypical antipsychotic drugs ( olanzapine ) and selective serotonin and then draw inhibitor (fluoxetine ) combined with the application of the treatment of schizophrenia .
Last year was greatly improved ,the first time has four drugs simultaneously approved or listed .This atypical antipsychotic drugs asenapine maleate ( Saphris Schering-Plough and Merck ;,2007 love color coating choose regression theme - whim blog,now merged ) is a kind of two-way serotonin ,since 5 -serotonin 2 receptor antagonist,dopamine D1 / D2 receptor antagonist ,in the United States won two categories related to indications of approval .
For adult schizophrenia and acute treatment, as well as manic or mixed bipolar disorder treatment . Asenapine in Europe is also undergoing review ,develop commodity The name Sycrest. Vanda in 2009 May to obtainpharmaceutical issued by FDA iloperidone ( Fanapt ) of the listing approval ,this is another atypical 5HT 2 anddopamine D-2 receptor antagonists.
Iloperidone for adult acute treatment of schizophrenia .Approval based on two placebo-controlled phase three clinical trials ,tests the drug on schizophrenia patients were 4 to6 weeks of treatment;phase compared to placebo and controlled drug (ziprasidone and risperidone ) ,the test drug showed good control schizophrenia effect.
At the end of the company announced and Novartis sales agreement ,Novartis will be responsible for the drug in the United States and Canada sales and marketing operation ;the drug plans in 2010 listed in the United States in January.
According to the estimation of the United States of America antipsychotic drug market is around $14000000000. Lilly ZypadheraTM ( olanzapine pamoate ) is the existing antipsychotic drug olanzapine ( Zyprexa ) long-acting injection type ,first to last listed ,for oral administration of olanzapine in the treatment of acute schizophrenia followed by maintenance therapy.
Global mental Biology Association Guide shows in spirit division long-term treatment in dependence of low is the greatest problem. When patients show the simple treatment Methods the favor when should consider the use of such formulations .
Pamoate salt preparation can make olanzapine sustained release for 4 weeks . Zypadhera March in Norway listed first ,and in several other European countries listed ,including Germany ,Ireland ,Finland ,Holland and Denmark ,and New Zealand ( trade name Zyprexa Relprew ) to the drug .
The middle of December received FDA approval ;trade name for Zyprexa Relprew. Paliperidone palmitate ( Invega Sustenna TM ) is an atypical antipsychotic drugs Paliperidone suspension injection type ,obtained last year American FDA approved and is listed on the Janssen .
For adult schizophrenia in the acute and maintenance treatment . Invega Sustenna is the first approved by the United States once a month ,long-acting atypical antipsychotic agents. Attention deficit disorder is the common emotional disorders ,about 5.
3% of the children are the victims ,the different manifestations .According to the Centers for Disease Control and prevention in the United States of America statistics ,there are about 4400000 4to 17 years old childrenwere diagnosed as attention deficit disorder .
Last year the United States of America attention-deficit / hyperactivity disorder in children and adolescent patients seen a new therapeutic agents :Shire IntunivTM ( guanfacine hydrochloride Guanfaci ) .
NE is a selective a-2A-adrenoceptor antagonists ,as antihypertensive drugs have been listed for decades. In the prefrontal cortex after a-2A-adrenoceptor synapses to be stimulated can improve working memory ,attentional modulation of force and action of inhibition ,reduced manic susceptibility and improve impulse control force .
Unlike prior attention disorders therapeutic drugs as a stimulus form of play ,guanfacine does not belong to the controlled drugs ,has no known underlying substance abuse or dependence. As a long-acting formulations ,Intuniy only needs to be taken once daily .
Nervous system drugs Eslicarbazepine acetate ( Zebinix ) is the Bial-Portela research and development of new antiepileptic drugs ,last year for the first time in the EU approved and listed in Germany and Austria by Eisai company ,responsible for marketing .
Eslicarbazepine is a novel sodium channel blockers ,the specificity of the effects on ion channels ,prevent its return to active state so as to reduce the repeated activation frequency .Indications for the treatment of the most common partial epilepsy .
Existing antiepileptic drug zonisamide is a sodium channel blockers and T type calcium channel blockers in Japan last year ,approval of new Indications: for the treatment of senile dementia complex levodopa.
This is occasionally observed with epilepsy in elderly patients with dementia by this in the treatment of senile dementia symptoms after the development of the indications. Based on this finding ,since 2001 the company began to research zonisamide in the treatment of senile dementia .
In the stage of clinical trials found efficacy include improvement in exercise function and activities of daily living ability ,especially for those of dopaminergic medications are ineffective in senile dementia .
The dopamine D2 /D3 receptor antagonist rotigotine ( Neupro ) as a treatment for senile dementia listing has a few years, last year in Britain and Germany to appear on the market ,new indications for the treatment of restless legs syndrome ( RLS ) .
The European clinical trials is fixed stoichiometry ,randomized ,double-blind, placebo controlled study on the efficacy and safety of Europe and the United States ,from nearly 1000 in severe congenitalRLS patients treated with rotigotine 6months validitywas evaluated .
Rotigotine ( 0.5-3mg/ 24h ) to evaluate the efficacy of using international hyperactivity leg syndrome severity assessment system ( IRLS ) .In addition ,severity of illness changes from global clinical impression ( CGI ) detection monitoring system evaluation.
In the two period of 6 monthsStudy of rotigotine had statistical significance and clinical observation of significant continued improvement. The European Commission in 2008 approved thesupplementary application .
In June, Cephalon launched the Nuvigi ( armodafini ) ,which is a modafinil persistent effect single isomers in the United States ;the medicine for improving sleepiness associated with sleep apnea patients symptoms and when working with narcolepsy symptoms .
Cephalon in the United States also received armodafinil approval ,for the treatment of sleepiness and jet lag .Norepinephrine serotonin reuptake inhibitor / milnacipran hydrochloride ( SavellaTM ) years ago to antidepressants as listed in the United States last year ,is approved for the treatment of fibromyalgia .
Milnacipran was for many years the third listing for treatment of the disease of drug ,by Cypress Bioscience from Pierre Fabre developed to obtain the drug patent ,and Forest with the collaborative marketing .
The drug phase three clinical trials in the United States of America Rheumatology college in October annual meeting ,compared to the placebo group ,milnacipran can relieve pain ,improve physical function and evaluation of patients with fibromyalgia .
Is a kind of chronic widespread pain accompanying somatic function decreased ,the United States of America About 6000000 of patients with autism and lonely .Affective disorder ( ASDs ) are a group of complex neurodevelopmental disorders ,there are three main characteristics :social function defects ,impaired function ,restriction and repeated exchange / interest behavior patterns of autistic children .
The most common character is irritable ,and attack others behavior and self-injury behavior ,irritability ,mood changes rapidly. Irritable character problem is ASD patients and their family tragedy .
Last November,Jeremy Scott Adidas, atypical antipsychotic drug aripiprazole ( Abilify ;Bristol-Myers Squibb / Otsuka ) is approved in the United States for the treatment of 6-17 years oldchildren with autism irritable bowel symptoms.
This is the one in 5,the serotonin 2A receptor inhibitors / 5 serotonin 1A receptorpartial inhibitor / dopamine D2 receptor partial inhibitors has been listed since 2002 for the treatment of various psychiatricdisorders ,including schizophrenia ,depression and bipolar disorder.
Another atypical antipsychotic drugs, risperidone2006 wonFDA approval for appropriate indications. Such drugs in the United States market :according to the Centers for Disease Control and prevention in 2009 December a reportin the United States ,one in 110 children has 1 peopleAutism .
Respiratory medicine intranasal corticosteroids in the treatment of allergic rhinitis has gradually become the first line drugs, especially in patients with severe symptoms and chronic rhinitis patients.
Intranasal corticosteroids applied to cause nasal congestion of allergic inflammation in the later stages. Preventive medication can also block the allergens in early stage. In general ,inhaled corticosteroids may be effective in relieving sneezing ,itching ,rhinorrhea and nasal congestion symptoms ,clinical analysis shows this kind of drug control of rhinitis than antihistamine drugs more effective.
Last year, the Nippon Shinyaku company in Japan was inhaled corticosteroid drugs dexamethasone cipecilate ( Erizas ) of the listing approval .This is the first in Japan for the treatment of allergic rhinitis by daily dose of inhaled corticosteroids .
November 30th long-term b2-adrenoceptor receptor antagonist ( indacaterol maleate Onbrez Breezhaler ;Novartis ) in the European Union approved the listing ,daily once for a chronic obstructive pulmonary disease ( COPD ) in adult patients with maintenance of airway dilation .
Indacaterol is the first and only one in clinical trials showed that 24 hoursof airway dilation effect and rapid ( 5 minutesafter inhalation inhalation ) Expanding the airway effects of drugs .
In addition ,it is also the first time in 7 years in Europe for approved drugs for COPD ,Europe has 82000000 patients.The drugs listed in Germany in November .Aztreonam lysinate ( Cayston ) is Gilead company developed aztreonam suction specific preparation .
In Europe in 2009 approvedfor the treatment of Pseudomonas lead cystic fibrosis patients with pulmonary infection. The United States FDA Drugs Advisory Committee also recommended approval of the drug ,and is scheduled for February 13, 2010 .
By Altera Nebulizer ( PARI pharmaceutical research and development of the product is a dedicated agency ) research and development of the complex is a broad spectrum of grand negative bacteria activity of single ring beta lactamase antibiotic .
Gilead announced it will debut in 2010 in Europe .Cardiovascular drugs in recent years ,more and more new antihypertensive compound listed ,are in a simplified way ,improve the compliance of taking it .
Last year, Novartis acquired the drug approval :a FDA Exforge HTC ,is a calcium channel blocker amlodipine ,angiotensin receptor blockers ( ARB ) valsartan and diuretics hydrochlorothiazide Ke Niaosai complexes ,one tablet daily .
Exforge HTC is the first in a single tablet A composite of several different drug antihypertensive drugs .Last April by FDA approved ,early June listed .Subsequently approved in Europe ,the trade name Exforge HCT ,Dafiro HCT and Imprida HCT.
In September, American FDA approved the first global Valturna ( aliskiren fumarate / valsartan ) ,which is developed by Novartis second treatment of artery high pressure composite drug .
Valturna ARB valsartan and direct renin inhibitor aliskiren compound in a tablet ,is one of the first acts on the renin - angiotensin - aldosterone system two target drug .The drug is used for a single aliskiren or ARB treatment does not control ,need more combined drug therapy of severe hypertension .
Novartis10 beginning in Augustmarketing of the drug. Boehringer Ingelheim Twynsta ( telmisartan / amlodipine besylate ) was third in the treatment of hypertension combined with drugs ,in the autumn of 2009 the United Statesapproved and listed .
Clinical studies show that Twynsta depressurizing range up to 40 / 29mmHg,there is a risk of cardiovascular disease in hypertensive patients 24 hours response rate of up to 98% ,including diabetes ,aging and obesity patients .
Twynsta has been approved in Europe and Japan ,in other regions of the world have submitted applications .Three classes of antiarrhythmic agents dronedarone hydrogen chloride ( Multaq ;sanofiaventis ) last year for the first time in the United States approved and listed ,for reducing paroxysmal or persistent atrial flutter ( AFL ) ,atrial fibrillation ( AF ) for cardiovascular events in patients at risk of hospitalization .
Clinical trials was randomized ,double-blind ,Adidas Jeremy Scott Schuhe,multinational study of ATHENA, dronedarone treatment evaluation atrial fibrillation patients in hospitalization or death risk ,compared with the placebo group found that risk can be reduced by 24% .
Go to the end of the drug in Canada and Europe were approved. 2009May,American FDA approved combination therapy for the treatment of pulmonary arterial hypertension ( PAH ;WHO class) drug phosphodiesterase PDE5 tadalafil( Adcirca ) .
The drug is applicable to the treatment of many types of pulmonary arterial hypertension ,including congenital and familial PAH ,as well as with scleroderma and congenital heart disease. The drug business marketing approval by Lily company ,Lily in 2003 the successful marketing ofthe tadalafil in the treatment of erectile dysfunction indications.
Last August the drugs with new indications in the United States and market access to rare disease therapeutic drug identity. The end of the new indications in Japan and the EU were approved.
Another one for the treatment of PAH NEW Medicine by combined treatment of last year the company launched in the United States :TyvasoTM ( treprostinil inhalants ) .Prior prostaglandin analogues are injection ( subcutaneous or intravenous ) form.
This efficacy by lasted 12 weeks ,randomized ,double-blind ,placebo-controlled clinical trials prove that the TRIUMPH-1 ,in the test received 4 days of Twaso inhalation in the treatment of patients in 6 minutes ofaction distance than the placebo control group by more than 20 meters.
As Twaso approved, combined treatment company also promised to suspend the drugs listed marketing pace, in order to further improve the suction system .Through the availability of collection and analysis of pharmacokinetic data analysis to determine the modified dose .
The company reported that the study progress ,improved suction system will be more friendly. Renal urinary system drugs Gelnique is a novel muscarinic antagonists of oxybutynin chloride gel preparation by Waston company ,R & D ,2009 inthe United States approved the listing .
For the treatment of bladder radical disease causing urinary incontinence and frequent micturition ,urinary urgency . Gelnique for both sexes are effective ,but listed only in female patients.
This was in response to the disease, the first and only the gel formulation .Clean ,dry aromatic gel daily used once, applied to the thigh ,abdomen ,arm or shoulder to provide continuous anticholinergic drug oxybutynin 24 hours oftreatment.
This transdermal formulation has several advantages ,especially to avoid first pass metabolism effect ,which is the result of oxybutynin of the most common mouth dry ,constipation as a side effect from 2009May,approved by the FDA .
Otsuka ( Samsca ) ,is an oral selective vasopressin V2 receptor antagonist ,for the treatment of severe hypervolemic and euvolemic hyponatremia ,including heart failure ,atherosclerosis and inappropriate antidiuretic hormone syndrome ( SIADH ) .
FDA approved a months get EU approval of clinical trials ,based on the SALT-1 and SALT-2results show thatdaily oral one tolvaptan can enhance SIADH patients with serum sodium concentration .
Otsuka company in June will be the medicine to the American market .In 2009 February,Janssen-Cilag dapoxetine hydrochloride ( PriligyTM ) in Finland and Sweden to get listed licensed for the treatment of 18-64old malepremature ejaculation .
In Europe there are seven were approved :Sweden ,Austria ,Finland ,Germany ,Spain ,Italy and Portugal .The program .In 2008 December,Finland and Sweden became the worldwide first approved the drug listing of countries .
In the ejaculation process serotonin is thought to play a major role . Dapoxetine is a unique ,short-acting ,selective serotonin reuptake inhibitors ,can be taken . Dapoxetine efficacy and safety by Johnson & Johnson placebo controlled phase three clinical tests ,including 6000of premature ejaculationin male patients and its companion participation ,this was in response to the disease as one of the biggest test of the hematological system drugs .
P2Y12 (P2T ) antagonist prasugrel ( Efient ) first last year in February the EU approved by Lily3 for the month ,launched in the UK in April ,the German market. In Europe are indications for percutaneous coronary intervention therapy for prevention of acute coronary syndrome ( PCI ) ( ACS ) in patients with thrombosis .
Prasugrel block platelet surface receptors ,and thus inhibits platelet aggregation and agglomeration. In a large-scale phase three clinical trials of the drug significantly reduced ACS in patients with cardiovascular event risk .
The drug by Daiichi of Sankyo company and Ube company cooperation research and development ,by Daiichi Sankyo company and Lily company cooperation marketing .At the end of the medicine in the The United States approved the listing of goods ,named EffientTM ,for PCI after treatment in patients with ACS or composite cardiovascular symptoms in patients with thrombosis in two grade prevention ;reduce death ,stroke and myocardial dissolved ,due to severe angina rehospitalization rate.
In 2009 Novemberplasma plasminogen activator inhibitor tranexamic acids ( Lysteda TM ;Xanodyne Pharmaceuticals ) access to the United States of America FDA approval ,for the treatment of menorrhagia ,overdose .
Lysteda is tranexamic acid oral activated formulations ;injection ( Cyklokapron ) in early 1986 on the market.The medicine is the first treatment of the disease of non-hormonal drugs ,the United States of America reproductive period of a woman of about 10% suffer from the disease.
Cause excessive bleeding causes and abnormal blood clot .As a resistance to plasminogen material ,Lysteda reduces its activity ,thereby contributing to the normal menstrual bleeding process of natural end.
A placebo-controlled phase three clinical trial results showed that the drug reduced monthly menstrual blood loss .In 2009 February BiotestAG coagulation factor IX ( Haemonine ) in Germany for listing .
B von Willebrand disease in the acute and prophylactic treatment .At the end of 2008, the medicine in the European Union obtained approval ;Germany was the first country in AMAG pharmaceutical listed .
Ferumoxytol ( Feraheme ) is a kind of new iron replacement therapy ,in the United States for the first time last year was approved . Ferumoxytol is an intravenous injection, used in the treatment of chronic kidney disease ( CKD ) and iron deficiency anemia in adult patients.
In all of the safety and efficacy of a phase three clinical trial evaluation, for the CKD and iron deficiency anemia patients with oral iron therapy ,comparative ,took the drug for 35 daysbefore the greatly improved .
Ferumoxytol by semi synthetic carbohydrate encapsulated superparamagnetic ferrite particle composition ,than ordinary oral iron preparations with high biological activity ,deputy reaction is little .
Gastrointestinal drugs proton pump inhibitor ( PPI ) dexlansoprazole ( KapidexTM ;Takeda ) last year in the United States approved the listing ,for the treatment of gastroesophageal reflux cause heartburn ,prompting esophagitis ulcer healing and maintenance of normal state.
Although there is a variety of PPI drugs exist ,Jeremy Scott Adidas,but the drug because of its unique highlight different sustained-release preparation ,the preparation can be divided into two independent release of drug .
Kapidex capsule contains two types of enteric coated particles can lead to a two release medicine :the first peak occurring after taking 1-2 hours,adidas Jeremy Scott Wings 2,second occurred in the hours after taking 4-5.
It only needs to be taken once daily ,the food of the Pru effect .Calopride is Movetis company developed selective high affinity of 5 serotonin receptor antagonist ,in 2009 Octoberapproved in the United States for the treatment of female chronic constipation .
Turn to doctors of patients with constipation in women account for 80-85%.Movetisprogram in Germany ,Britain ,France and Belgium ,Holland ,Luxemburg and other European countries by their own marketing .
If necessary, Movetis will seek partners in other European regions in order to maximize the drug sales. Is expected the first quarter of 2010 in Germanyhas been the first listed .Endocrine drugs with the 2009 July,the European Commission approval ,human glucagon like peptide 1 (GLP-1 )receptor antagonist and imitation secreted peptide liraglutide ( Victoza ;Novo Nordisk ) first appeared in the UK the.